Dec 8 (Reuters) - The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help ...
FDA sought policy recommendations on mental health medical devices, including AI-enabled. After I reviewed submissions, one ...
Had DOGE embraced an AI-first strategy, the United States might today be leading the world in digital governance, offering ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their ...
The agency’s sweeping rollout and staff challenge underscore rising momentum behind agentic AI: advanced, multiagent systems ...
5don MSN
US FDA approves first AI tool for liver disease trials: How AIM-NASH transforms biopsy reading
A groundbreaking AI tool, AIM-NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative ...
For those who want to see a doctor, supported by AI or not, opting for care at outpatient facilities or telehealth options ...
PathAI, a global leader in AI-powered pathology, today announced that the U.S. Food and Drug Administration (FDA) has ...
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
Resmed (NYSE: RMD) announced today that it received FDA clearance for its Smart Comfort personalized therapy comfort settings ...
Deputy Secretary of the Department of Health and Human Services Jim O’Neill is bringing a Silicon Valley attitude to AI use and regulation at the agency. | At an event hosted on Wednesday, O'Neill ...
The U.S. Food and Drug Administration (FDA) announced it is using various artificial intelligence tools to use in premarket reviews and for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback